Long-Term Results of Interstitial Laser Coagulation for the Treatment of Benign Prostatic Obstruction

Objectives: Long term data on the outcome of interstitial laser coagulation for the treatment of sub vesical obstruction due to benign prostatic enlargement have been rarely published. Our long-term outcome data are presented and the technique of interstitial laser coagulation is critically evaluated. Methods: We carried out an evaluation of the outcome of consecutive interstitial laser coagulation procedures between 1999 and 2004. Follow-up was done by questionnaires sent to the outpatient urologists and by telephone interviews of patients. Results: 68 patients were treated with ILC. Follow up was available for 66 patients (97%). Mean follow up was 41 months, 40 of 66 patients have been voiding spontaneously after ILC treatment (61%). Mean residual urine volume of these patients at the time of follow up was 25 ml (0-120 ml). Mean Qmax at the time of follow-up was 11.1 ± 4.5 ml/sec. 16 patients have needed a secondary procedure for bladder outlet obstruction (TURP in most of these) and have been catheter-free since that. 10 patients remained on catheter drainage. A history of high residual urine volume or urinary retention was identified as predictor for treatment failure. Conclusion: Interstitial laser coagulation can be used in selected patients with multiple comorbidities for the treatment of benign prostatic hyperplasia. *Corresponding author: Stefan Zastrow, University Hospital Dresden “Carl Gustav Carus”, Department of Urology, Fetscherstrasse 74, 01307 Dresden, Germany, Tel: 493514582447; Fax: 493514584333; E-mail: [email protected] \ Received April 29, 2014; Accepted June 22, 2014; Published June 28, 2014 Citation: Zastrow S, Oehlschlaeger S, Froehner M, Leike S, Novotny V, et al. (2014) Long-Term Results of Interstitial Laser Coagulation for the Treatment of Benign Prostatic Obstruction. Med Surg Urol 3: 138. doi:10.4172/2168-9857.1000138 Copyright: © 2014 Zastrow S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.